Intraoperative subconjunctival bevacizumab as an adjunctive treatment in primary pterygium: A preliminary report

Ophthalmic Surgery Lasers and Imaging

Volumn 43, Issue 6, 2012, Pages 459-466

  Shahin, Maha M ^a   Elbendary, Amal M ^a   Elwan, Mohamed M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAOPERATIVE PERIOD; MALE; PRIORITY JOURNAL; PTERYGIUM; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK REDUCTION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHEMOTHERAPY, ADJUVANT; CONJUNCTIVA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PTERYGIUM; VISUAL ACUITY;

EID: 84872694001     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20120802-02     Document Type: Article

References (43)

1. Dushku N, Reid TW. Immunohistochemical evidence that human pterygia originate from an invasion of vimentin-expressing altered limbal epithelial basal cells. Curr Eye Res. 1994;13:473-481.
2. Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol. 1999;10:282-288.
3. Cameron ME. Pterygium Throughout the World. Springfield, IL: Charles C. Thomas; 1965;141.
4. Cilova-Atanasova B. On the pathogenesis of pterygium. Folia Med. 1971;13:67-74.
5. Hill JC, Maske R. Pathogenesis of the pterygium. Eye. 1989;3:218-226.
6. Pinkerton OD, Hokama Y, Shigemura LA. Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol. 1984;98:225-228.
7. Solomon AS. Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol. 1985;99:216-217.
8. Tsironi S, Ioachim E, Machera M, Aspiotis M, et al. Immunohistochemical HLA-DR antigen expression with lymphocyte subset and proliferative activity in pterygium. In Vivo. 2002;16:299-306.
9. Busin M, Halliday BL, Arffa RC, McDonald MB, Kaufman HE. Precarved lypholized tissue for lamellar keratoplasty in recurrent pterygium. Am J Ophthalmol. 1986;102:222-227.
10. Prabhasawat P, Tesavibul N, Leelapatranura K, Phonjan T. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology. 2006;113:1102-1109.
11. Na KS, Kim JY, Choi GJ. A clinical observation on the argon laser effect of the pterygium. J Korean Ophthalmol Soc. 1996;37:1120-1125.
12. Talu H, Tasindi E, Ciftci F, Yildiz T F. Excimer laser phototherapeutic keratectomy for recurrent pterygium. J Cataract Refract Surg. 1998;24:1326-1332.
13. Ma DH, See LC, Liau SB, Tsai RJ. Amniotic membrane graft for primary pterygium: comparison with conjunctival autograft and topical mitomycin C treatment. Br J Ophthalmol. 2000;84:973-978.
14. Gebhardt M, Mentlein R, Schaudig U, et al. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology. 2005;112:1023-1230.
15. Aspiotis M, Tsanou E, Gorezis S, et al. Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye. 2007;21:1095-1101.
16. Manzano RPA, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807.
17. Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Daqli O, Durukan AH. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea. 2008;27:357-362.
18. Wu PC, Kuo HK, Tai MH, Shin SJ. Topical bevacizumab eye drops for limbal: conjunctival neovascularization in impending recurrent pterygium. Cornea. 2009;28:103-104.
19. Fallah MR, Khosravi K, Hashemian MN, Beheshtnezhad AH, Rajabi MT, Gohari M. Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res. 2010;35:17-22.
20. Mansour AM. Treatment of inflamed pterygia or residual pterygial bed. Br J Ophthalmol. 2009;93:864-865.
21. Teng CC, Patel NN, Jacobson L. Effect of subconjunctival bevacizumab on primary pterygium. Cornea. 2009;28:468-470.
22. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Sub-conjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008;3:23-28.
23. Tan DT, Chee S P, Dear KB, Lim AS. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol. 1997;115:1235-1240.
24. Sangwan V, Murthy SI, Bansal AK. Surgical treatment of chronically recurrent pterygium. Cornea. 2003;22:63-65.
25. Dadeya S. Autografting of marginal conjunctiva. Ophthalmologica. 2003;217:237-238.
26. Maheshwari S. Split-conjunctival grafts for double head pterygium. Indian J Ophthalmol. 2005;53:53-55.
27. Dadeya S, Malik K P, Gullian B P. Pterygium surgery: conjunctival rotation autograft versus conjunctival autograft. Ophthalmic Surg Lasers. 2002;33:269-274.
28. Rao SK, Lekha T, Mukesh BN, Sitalakshmi G, Padmanabhan P. Conjunctival-limbal autografts for primary and recurrent pterygia: technique and results. Indian J Ophthalmol. 1998;46:203-209.
29. Gris O, Güell JL, del Campo Z. Limbal-conjunctival autograft transplantation for the treatment of recurrent pterygium. Ophthalmology. 2000;107:270-273.
30. Al Fayez MF. Limbal versus conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology. 2002;109:1752-1755.
31. Todani A, Melki SA. Pterygium: current concepts in pathogenesis and treatment. Int Ophthalmol Clin. 2009;49:21-30.
32. Chen P P, Ariyasu RG, Kaza V, LaBree LD, McDonnell PJ. A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. Am J Ophthalmol. 1995;120:151-160.
33. Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet-derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem. 1996;98:195-201.
34. Kria L, Ohira A, Amemiya T. Growth factors in cultured pterygium fibroblast: immunohistochemical and ELISA analysis. Graefes Arch Clin Exp Ophthalmol. 1998;236:702-708.
35. Pérez-Santonja JJ, Campos-Mollo E, Lledó-Riquelme M, Javaloy J, Alio JL. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and sunitinib (Anti-VEGF and Anti-PDGF) in an animal model. Am J Ophthalmol. 2010;150:519-528.
36. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol. 2006;142:660-668.
37. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611.
38. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335.
39. Berthaut A, Mirshahi P, Benabbou N et al. Vascular endothelial growth factor receptor-1 (VEGFR-1) expression in human corneal fibroblast decreased with age. Mol Vis. 2009;15:1997-2007.
40. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:e33-e38.
41. Galor A, Yoo SH. Corneal melt while using topical bevacizumab eye drops. Ophthalmic Surg Lasers Imaging. 2010;9:1-3.
42. Van Bergen T, Vandewalle E, Van de Veire S, et al. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Exp Eye Res. 2011;93:689-699.
43. Stalmans I, Ng YS, Rohan R, et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest. 2002;109:327-336.